Parameter
| Biomarker | Circulating Tumor DNA (ctDNA) | Full name | Circulating Tumor DNA | Molecular Type | Nucleic acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis and monitoring treatment response | ||
| Disease | Hepatocellular Carcinoma (HCC) | Disease Subtypes | / | ||
| Organ | Liver | Test Sample / Technology Platform | Plasma (NGS, digital PCR, methylation sequencing) | ||
| Pathobiological Mechanisms | Mutated DNA fragments released by apoptosis/necrosis of tumor cells reflect the mutation spectrum of tumor genes | ||||
| Clinical Availability Status | TERT, TP53, CTNNB1 and other mutations could be detected | ||||
| Notes and Dynamics | Methylation ctDNA markers (such as DBX2, TGR5) in early diagnosis of the sensitivity of 87%, is expected to be in clinical | ||||